Skip to main content

Table 2 Follow-up rate and percentage with timely follow-up for women with screening abnormality stratified by screening processes

From: Delays in follow-up among women with abnormal results: a retrospective study based on population-based breast cancer screening programme in China

Screening processes

Total

Site A

Site B

Site C

US (suspicious) → MAMa

    

 Follow-up rate (%)

76.13(5824/7650)

99.84(2533/2537)

81.66(2938/3598)

23.30(353/1515)

 Timely follow-up ratee (%)

60.29(4612/7650)

80.65(2046/2537)

61.76(2222/3598)

22.71(344/1515)

 Follow-up timee (median, IQR)

27 (2, 238)

15(2, 52)

14(2,202)

> 365

 Timely follow-up ratef (%)

79.19 (4612/5824)

80.77 (2046/2533)

75.63 (2222/2938)

97.45 (344/353)

 Follow-up timef (median, IQR)

8 (1, 49)

15 (1, 52)

7 (1, 54)

2 (0, 5)

MAM (positive) → Biopsyb

    

 Follow-up rate (%)

63.21 (177/280)

68.00(85/125)

86.25(69/80)

30.67 (23/75)

 Timely follow-up ratee (%)

48.93 (137/280)

53.60(67/125)

62.50(50/80)

26.67 (20/75)

 Follow-up timee (median, IQR)

66 (20, > 365)

51 (20, >365)

40.5(9.5,88)

> 365 (36.5,>365)

 Timely follow-up ratef (%)

77.40 (137 /177)

78.82 (67/85)

72.46 (50/69)

86.96 (20/23)

 Follow-up timef (median, IQR)

25 (10, 53)

26 (15, 51)

25 (8, 62)

21 (8.5, 33)

US (positive) → Biopsyc

    

 Follow-up rate (%)

66.09 (191/289)

92.50(111/120)

47.34(80/169)

-

 Timely follow-up ratee (%)

43.94 (127/289)

55.00(66/120)

36.09(61/169)

-

 Follow-up timee (median, IQR)

89 (16, > 365)

49 (13.8, 111)

>365 (22,>365)

-

 Timely follow-up ratef (%)

66.49 (127/191)

59.46 (66/111)

76.25 (61/80)

-

 Follow-up timef (median, IQR)

31 (9, 84.5)

43 (11, 97)

20.5 (8, 57)

-

US (suspicious/positive) → Diagnostic examination (including MAM/biopsy)d

    

 Follow-up rate (%)

74.86 (5943/7939)

98.01 (2604/2657)

79.82 (3007/3767)

21.91 (332/1515)

 Timely follow-up ratee (%)

58.33 (4631/7939)

77.83 (2068/2657)

59.76 (2251/3767)

20.59 (312/1515)

 Follow-up timee (median, IQR)

33(3,>365)

19(2, 56)

18(2,214)

>365

 Timely follow-up ratef (%)

77.92 (4631/5943)

79.42 (2068/2604)

74.86 (2251/3007)

93.98 (312/332)

 Follow-up timef (median, IQR)

10 (1, 53)

18 (2, 54)

7 (1, 61)

2 (0, 8)

  1. a Women with BI-RADS categories 0 or 3 in US (suspicious results) were provided with supplemental MAM in Site A and B, while those with BI-RADS categories 0, 4, or 5 in US (suspicious results) were referred to Site C; b Women with BI-RADS categories 4 or 5 in MAM (positive results) required a biopsy in Site A and B, but those with BI-RADS categories 0, 4, or 5 in US (positive results) in MAM were required in Site C; c Women with BI-RADS categories 4 or 5 in US (positive results) were directly referred for biopsy only at Site A and B; d The follow-up rate for the entire procedure between US and the diagnostic testings including: (1) US (with a positive result)→biopsy, (2) US (with a suspicious result)→MAM (with a negative result), (3) US(with suspicion result) →MAM (with a positive result)→biopsy, (4) US (with suspicion result)→biopsy (without following screening protocol); e Including women who did not complete follow-up; f Excluding women who did not complete follow-up
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us